<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023240</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-52129</org_study_id>
    <nct_id>NCT04023240</nct_id>
  </id_info>
  <brief_title>68-Ga-FAPI PET Imaging in Malignancy</brief_title>
  <official_title>68Ga-FAPI PET Imaging in Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This feasibility trial studies the use of gallium-68 (68Ga)-FAPI as the imaging agent for
      positron emission tomography (PET)/computed tomography (CT), collectively PET/CT, in patients
      with various cancers. PET uses a radioactive substance called 68Ga-FAPI, which attaches to
      cancer activated fibroblasts. The PET scanner takes pictures that capture where the
      radioactive drug is &quot;lighting up&quot; and attaching to tumor cells, which may help doctors
      recognize differences between tumor and healthy tissue. CT uses X-rays to make a picture of
      areas inside the body. Using 68Ga-FAPI in diagnostic procedures, such as PET/CT, may allow
      doctors to identify smaller tumors than standard imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      To assess feasibility and biodistribution of PET imaging in malignancy using 68Ga-FAPI.

      OUTLINE:

      Patients receive 68Ga-FAPI intravenously (IV) and then undergo PET/CT approximately 1 hour
      later.

      After completion of study, patients are followed up at 24-72 hours.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2019</start_date>
  <completion_date type="Anticipated">December 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of 68Ga-FAPI PET</measure>
    <time_frame>24 months</time_frame>
    <description>Feasibility of 68Ga-FAPI PET/CT imaging will be done to assess patients with malignancy. Feasibility will be measured using Likert scale (1-non diagnostic; 5-excellent; anything 3 or more is diagnostic). The study will be feasible if &gt; 50% of scans will have a score of 3 or more</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-FAPI PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-FAPI</intervention_name>
    <description>68Ga-FAPI is quinoline based PET radiopharmaceutical.
68Ga-FAPI is administered intravenously (IV)</description>
    <arm_group_label>68Ga-FAPI PET/CT</arm_group_label>
    <other_name>68-Ga-Fibroblast activation protein inhibitor (FAPI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography (CT) scan</intervention_name>
    <description>Participants will have a CT scan for attenuation correction and anatomic localization of PET data.</description>
    <arm_group_label>68Ga-FAPI PET/CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography (PET) scan</intervention_name>
    <description>PET images will be acquired.</description>
    <arm_group_label>68Ga-FAPI PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with current malignancy confirmed via pathology or imaging

          -  Patient must be &gt; 18 years old

          -  Patient must be willing and able to provide written informed consent for the trial

          -  Patient of reproductive potential will have a pregnancy test

        Exclusion Criteria:

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carina Mari, MD</last_name>
    <phone>650-725-4711</phone>
    <email>drmari@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Risa Jiron</last_name>
    <phone>650-736-1598</phone>
    <email>rjiron@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

